Home » Stocks » CRBP

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Stock Price: $1.40 USD -0.08 (-5.41%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 185.05M
Revenue (ttm) 2.82M
Net Income (ttm) -97.68M
Shares Out 116.34M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $1.40
Previous Close $1.48
Change ($) -0.08
Change (%) -5.41%
Day's Open 1.48
Day's Range 1.39 - 1.49
Day's Volume 844,811
52-Week Range 0.91 - 9.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 hour ago - Zacks Investment Research

Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other stocks mentioned: ABUS, ARPO, DBGI, JFU, NBY, NXE
3 weeks ago - PennyStocks

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

Other stocks mentioned: AFCG, ARNA, CGC, EVGN, IGC, OGI, SNDL ...
1 month ago - Schaeffers Research

Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflamm...

1 month ago - GlobeNewsWire

Important events on the horizon could push these biotech stocks higher or press them further into the dirt.

Other stocks mentioned: GMTX, NTLA
1 month ago - The Motley Fool

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

PSY (PSY) is getting extra attention on Monday as investors seek out new investments in the psychedelic medical market today. The post PSY: 14 Things to Know About the First Psychedelic Stocks ETF in th...

Other stocks mentioned: ACB, CRON, CWBHF, SPRWF, TWTR
1 month ago - InvestorPlace

You might want to avoid buying it, though.

1 month ago - The Motley Fool

Norwood, MA, June 01, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced licensing deals for two new monoclonal antibodies (mAbs),...

1 month ago - GlobeNewsWire

Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News a...

Other stocks mentioned: EYES, TYME
2 months ago - PennyStocks

Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici...

2 months ago - GlobeNewsWire

Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals H o ldings, Inc.  (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

2 months ago - GlobeNewsWire

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

Other stocks mentioned: ACB, APDN, ARNA, CARA, CGC, FLGC, GRWG ...
2 months ago - Schaeffers Research

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 67.44% year over year to ($0.14), which beat the estim...

2 months ago - Benzinga

Norwood, MA, May 13, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici...

2 months ago - GlobeNewsWire

Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici...

2 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...

Other stocks mentioned: APHA, ARNA, CGC, GWPH, IIPR, JAZZ, NEPT ...
3 months ago - Schaeffers Research

Norwood, MA, April 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...

3 months ago - GlobeNewsWire

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...

Other stocks mentioned: GNLN, HUGE, IIPR, NTEC, OGI
3 months ago - Schaeffers Research

Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...

3 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) moved higher by 5.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 75.61% year over year to ($0...

4 months ago - Benzinga

As usual, no earnings reports are scheduled for release on Friday afternoon. And with just two weeks to go in the first calendar quarter of 2021, there are only two earnings reports that we think are wo...

4 months ago - 24/7 Wall Street

Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...

4 months ago - GlobeNewsWire

•   Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET

4 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

If January and February are a sign of things to come in 2021, traders and investors are going to make a lot of money this year. 4 hot small cap stocks on the move are Corbus Pharmaceuticals (NASDAQ: CRB...

Other stocks mentioned: MJNA, MVIS, REZZF
5 months ago - OTC PR Wire

Inside the top performing stocks in the top ETF of January.

Other stocks mentioned: APHA, CGC, HEXO, POTX, TLRY
5 months ago - Zacks Investment Research

Major disappointment last year due to lenabasum not meeting its endpoints in a phase 3 and phase 2 trial. Massive expectation meant that the company had to downsize significantly to keep operations going.

6 months ago - Seeking Alpha

Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

6 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Corbus Pharma (CRBP) is seeing massive gains for CRBP stock on Tuesday despite a lack of recent news from the pharmaceuticals company. The post Corbus Pharma: 8 Things for CRBP Stock Investors to Know A...

7 months ago - InvestorPlace

Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

8 months ago - GlobeNewsWire

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) CEO Yuval Cohen On Q3 2020 Results - Quick Version Earnings Call Transcript

8 months ago - Seeking Alpha

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -4.88% and -64.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.6% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 34.37% year over year to ($0.43), whi...

8 months ago - Benzinga

Norwood, MA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

8 months ago - GlobeNewsWire

On Tuesday, November 10, Corbus Pharmaceuticals (NASDAQ: CRBP) will release its latest earnings report. Benzinga's outlook for Corbus Pharmaceuticals is included in the following report.

8 months ago - Benzinga

Norwood, MA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

8 months ago - GlobeNewsWire

Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

8 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Norwood, MA, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

9 months ago - GlobeNewsWire

Norwood, MA, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

9 months ago - GlobeNewsWire

Norwood, MA, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

9 months ago - GlobeNewsWire

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for... [Read more...]

Industry
Biotechnology
Founded
2009
CEO
Yuval Cohen
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
CRBP
Full Company Profile

Financial Performance

In 2020, CRBP's revenue was $3.94 million, a decrease of -89.11% compared to the previous year's $36.14 million. Losses were -$111.27 million, 55.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CRBP stock is "Hold." The 12-month stock price forecast is 2.10, which is an increase of 50.00% from the latest price.

Price Target
$2.10
(50.00% upside)
Analyst Consensus: Hold